CRESO PHARMA LIMITED (CPH)

name changed to Melodiol Global Health Limited

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately following the release by CPH of an announcement regarding a capital raising.

ï‚· Firm commitments to raise $7m equity at a issue price of $0.04 (4 cents). $1.74m of the Placement was cornerstoned by CPH Directors Bruce Linton, Adam Blumenthal and William Lay. EverBlu Capital Corporate Pty Ltd acted Lead Manager and Perth-based CPS Capital Group Pty Ltd acted as Co-Manager. In line with the Company's objective to bring the group to cash flow positive in 3-4 quarters, Creso Pharma continues to reduce cash burn across the entire business. Net cash used in operating activities decreased 45% from A$3,675,000 in Q1 2022 to A$2,008,000 in the previous quarter, Q2 2022. Creso Pharma Group's unaudited group revenue in H1 was $4,314,308 (not including Sierra Sage Herbs LLC. SSH Group Q1 2021 revenue was US$1.5m, with Q2 revenue of US$1.1m "“ decrease was related to delay in closing the CPH takeover, merger integration and timing of customer orders. SSH's H1 unaudited revenue totalled US$2.6m "“ highlighting a strong start to 2022. Non-binding Term Sheet with Obsidian Global Partners, LLC (referred to in the Creso's quarterly) has been terminated.

The company wishes the voluntary suspension to remain in place until such time as the announcement in relation to a capital raising is released to the market, or until commencement of trade on Thursday, 4 August 2022.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

Creso Pharma Limited has signed a non-binding term sheet to acquire Health House International Ltd. The non-binding term sheet is conditional upon completion of satisfactory due diligence on Health House and the parties entering into a formal Scheme Implementation Deed, amongst other standard conditions. The acquisition is proposed to be undertaken by a Scheme of Arrangement pursuant to Part 5.1 of the Corporations Act 2001 (Cth).

The securities of Creso Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement regarding a capital raising.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately following the release by CPH of an announcement regarding a capital raise.

The company releases a notice of proposed issue of securities.

Firm commitments to raise $5m through the issue of approximately 72.4m new fully paid ordinary shares at an issue price of $0.069. Placement strongly supported by a range of local and international investors, including institutions and sophisticated investors. Funds to be deployed towards US expansion, general working capital, product development initiatives and other opportunities. Creso Pharma plans to grow its US footprint ahead of, and following the acquisition of, Sierra Sage Herbs LLC and leading Green Goo brand. Multiple growth initiatives underway with new funds providing financial flexibility.

The securities of Creso Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement regarding a capital raise.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately, following the release by CPH of an announcement regarding its sales and revenue

Total revenue generated during the quarter ended 30 June 2021 (Q2 CY2021) of A$1,715,933 "“ a 24% increase on the previous quarter (Q1 CY2021: A$1,385,000). Q2 CY2021 revenue marks a 451% increase on the previous corresponding period (Q2 CY2020: A$311,353). Strong sales growth witnessed through Swiss operations and wholly-owned Canadian subsidiary Mernova Medical Inc. Multiple purchase orders from various provinces highlight increased demand for Mernova's products in Canada and scalable recurring revenue model. Creso has a positive outlook on sales growth, with potential Red Light Holland merger providing multiple new near term market entries and scale up opportunities. Sales growth represents the second quarter of consecutive record revenue for the Creso Pharma Group. Ongoing growth demonstrates Company's strategy to create consistent revenue generation across all business divisions.

The securities of Creso Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement regarding a material sales and revenue update.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately, following the release of an announcement by CPH.

Following the mutual termination of the proposed acquisition of Creso Pharma by PharmaCielo Ltd, Creso Pharma will pursue the commercialistion of its innovative product portfolio, securing key certifications, exploring strategic partnerships and accelerating revenue growth. The company has se cured convertible debt and share placement financing to bolster itsbalance sheet and is now in a strong position to pursue its renewed growth strategy. Creso Pharma's current portfolio consists of 13 high-quality, "Swiss Made", GMP certified products, four of which have already been commercialised with the others being prepared for commercialisation. Creso Pharma's wholly-owned subsidiary Mernova Medical Inc. in Nova Scotia is revenuegenerating and is in the advanced stages of securing European GMP certification. Once it has secured GMP certification, Mernova will be one of very few EU GMP certified producers in Canada, allowing it to ship and sell to Europe, and specifically the high growth markets of Germany and Switzerland. Creso Pharma continues to explore strategic partnerships as it aims to expand the availability of its approved products to international patients and consumers.

The company obtained a waiver from ASX in relation to ASX Listing Rule 10.1 to permit Suburban Holdings to be issued the first tranche notes and, in particular, to be granted the securities.

The company issues a prospectus for the offer of: up to 6,111,111 debt notes each with a face value of $1.00 at a subscription price of $0.90 per debt note; and up to 10,000 Shares at an issue price of $0.20 per share to raise up to $2,000.

On 1 November 2019, Creso Pharma received a supplementary independent expert report from the Independent Expert opining that the Share Scheme is neither fair nor reasonable and not in the best interests of Creso Pharma shareholders. In light of the change in recommendation of the Independent Expert, Creso Pharma and PharmaCielo have mutually agreed that the SIA has been terminated. In connection therewith, on 11 November 2019, Creso Pharma and PharmaCielo executed an agreement of mutual release and settlement in relation to the SIA, whereby each of Creso Pharma and PharmaCielo agreed to release each other from all claims arising under or in connection with the SIA or the related transaction documents. Creso Pharma is required to repay the outstanding amounts of the loans advanced by PharmaCielo by 30 November 2019. Creso Pharma has made significant progress on these fundraising initiatives and expects to be in a position to finalise the terms of the fundraising on or prior to 15 November 2019.

The share scheme meeting and the option scheme meeting scheduled for today at 10:00am and 10:30am WST, respectively, were adjourned by the chairperson. The meetings will be reconvened as follows: share scheme meeting - 10:00 am WST; option scheme meeting - the later of the conclusion of the share scheme meeting and 10:15am WST on 18 November 2019 at Level 4, 16 Milligan St, Perth 6000.

The company is not in a position to release an announcement at this time, and accordingly, the company's securities will remain in voluntary suspension until the release of such announcement, which is expected to be made no later than 15 November 2019. The scheme meetings that were scheduled to be held on 11 November 2019 are anticipated to be adjourned.

The securities of Creso Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately, following the release by CPH of the scheme booklet pursuant to the scheme implementation agreement between CPH and PharmaCielo Limited.

The Supreme Court of Western Australia made orders yesterday that the company convene a meeting of its shareholders to consider and, if thought fit, approve the share scheme and a meeting of its listed optionholders to consider and, if thought fit, approve the option scheme. The Scheme Booklet will be released on the ASX shortly, following its registration with the ASIC. The Share Scheme Meeting and the Option Scheme Meeting will each be held at the office of Steinepreis Paganin, Level 4, The Read Buildings, 16 Milligan Street, Perth, Western Australia, on Monday, 11 November 2019, commencing with the Share Scheme Meeting at 10:00am (Perth time). The Option Scheme Meeting will commence at the later of the conclusion of the Share Scheme Meeting and 10:30am (Perth time). The Board of Directors of Creso Pharma continues to unanimously recommend that Creso Pharma shareholders and Listed Optionholders vote in favour of the proposed Schemes, in the absence of a superior proposal for Creso Pharma. If the Schemes are approved at the Scheme Meetings and all others conditions of the Schemes are satisfied or waived, the Company will apply to the Court for orders approving the Schemes.

The company provides an update on the proposed acquisition by PharmaCielo. PharmaCielo's share price continues its strong recovery. New Independent Expert's Report received and Creso Pharma proceeding to a First Court Hearing for the Schemes scheduled for 2 October 2019.

The securities of Creso Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement regarding the proposed acquisition of the Company by PharmaCielo Limited by way of schemes of arrangement pursuant to the Scheme Implementation Agreement announced to ASX on 7 June 2019.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately following receipt of an announcement regarding the potential transactions referred to in the cleansing statements of 31 January and 1 February 2019.

The Company wishes to confirm that as both the Potential Transactions are still in the preliminary negotiation phase, the terms and details of the Potential Transactions remain incomplete and insufficiently definite to warrant disclosure or certainty. Accordingly, it is not possible to form a definitive view on whether the Potential Transactions would trigger the application of Chapter 11 of the ASX Listing Rules. The ASX has advised that the Company's securities will be reinstated to trading at market open on 12 February 2019.

The company is currently in consultation with the ASX in relation to the application of Chapter 11 of the ASX Listing Rules to the two potential transactions that were previously disclosed in cleansing statements released by the Company on 31 January 2019 and 1 February 2019. Creso is working to have these discussions concluded shortly, and anticipates trading to recommence on or before Tuesday, 12 February 2019.

The securities of Creso Pharma Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CPH, pending the release of an announcement.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately, following receipt of an announcement.

The company has completed a heavily subscribed placement to raise AUD$17.5mn. They also provided an update on Kingdom and a new partnership with Aeschbach Chocolatier.

The securities of Creso Pharma Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to a capital raising, company update and information on entering Edibles with terpene infused chocolates.

The suspension of trading in the securities of Creso Pharma Limited will be lifted immediately, following receipt of an announcement.

The company has signed its first Australian letter of intent with Health House Internationl for the import and sale of cannabis products in the Australian market. Also, the company has opened an office in Sydney, giving it a presence on Australia's east coast, addin to its existing office in Perth.

The securities of Creso Pharma Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement.

listed entity carried for record purposes only